Zobrazeno 1 - 10
of 41
pro vyhledávání: ''
Autor:
Long hua Zhao, Jian Fei Wang, Wanping Hu, Li Zhong, Jin Chi Zu, Xu Gao, Xiao Gang Zhang, Kun Ge, Kemp H. Kernstine, Wei Ke Shen, Yun Yen
Publikováno v:
Breast Cancer Research : BCR
Introduction Only a limited number of tumor markers for breast cancer are currently available. Antibodies to tumor-associated proteins may expand the number of available tumor markers for breast cancer and may be used together in a serum profile to e
Autor:
Sophia Agelaki, Antonia Kalykaki, A. Xyrafas, Emmanouil Saloustros, Kostas Kalbakis, Galatea Kallergi, Dimitris Mavroudis, Stella Apostolaki, M. Perraki, Vassilis Georgoulias
Publikováno v:
Breast Cancer Research : BCR
Background The detection of cytokeratin-19 (CK-19) mRNA-positive circulating tumor cells (CTC) before and/or after adjuvant chemotherapy in patients with operable breast cancer is associated with poor clinical outcome. Reliable prognostic markers for
Autor:
Helena Hwang, Brian Z. Ring, Marshall T Schreeder, Nancy Watroba, Robert S. Seitz, Christine Murekeyisoni, Swati Kulkarni, Noel C Estopinal, Douglas T. Ross, David G. Hicks, Thaer Khoury, Rodney A. Beck
Publikováno v:
Breast Cancer Research : BCR
Introduction The addition of taxanes (Ts) to chemotherapeutic regimens has not demonstrated a consistent benefit in early-stage breast cancer. To date, no clinically relevant biomarkers that predict T response have been identified. Methods A dataset
Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer
Autor:
Brian M Nolen, Jeffrey R Marks, Shlomo Ta'san, Alex Rand, The Minh Luong, Yun Wang, Kimberly Blackwell, Anna E Lokshin
Publikováno v:
Breast Cancer Research : BCR
Introduction Neoadjuvant chemotherapy has become the standard of care for the diverse population of women diagnosed with locally advanced breast cancer. Serum biomarker levels are increasingly being investigated for their ability to predict therapy r
Autor:
Sarah Kirk, Tania Szado, Lukas C. Amler, Young-Hyuck Im, Jennifer Eng-Wong, Giampaolo Bianchini, Pinuccia Valagussa, Tadeusz Pienkowski, Luca Gianni, Giulia Bianchi, Lila Zabaglo, Mitch Dowsett, Astrid Kiermaier, Mei Ching Liu, Ling Ming Tseng
Publikováno v:
Breast Cancer Research : BCR
Background NeoSphere showed significantly higher pathologic complete response (pCR) with neoadjuvant pertuzumab, trastuzumab, and docetaxel compared with trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel. We assess
Autor:
Christin Gasch, Martina Auer, Ellen Heitzer, Klaus Pantel, Jochen B. Geigl, Gunda Pristauz, Oliver Mauermann, Sabine Riethdorf, Ingrid Lafer, Sigurd Lax, Peter Ulz, Edgar Petru, Michael R. Speicher, Maryam Heidary
Publikováno v:
Breast Cancer Research
Breast Cancer Research : BCR
Breast Cancer Research : BCR
Introduction The management of metastatic breast cancer needs improvement. As clinical evaluation is not very accurate in determining the progression of disease, the analysis of circulating tumor DNA (ctDNA) has evolved to a promising noninvasive mar
Autor:
Laura J. Esserman, John J. Sninsky, Christina Yau, Dan H. Moore, Christopher C. Benz, Fred Waldman
Publikováno v:
Yau, Christina; Esserman, Laura; Moore, Dan H; Waldman, Fred; Sninsky, John; & Benz, Christopher C. (2010). A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer. Breast Cancer Research, 12(5), R85. doi: http://dx.doi.org/10.1186/bcr2753. Retrieved from: http://www.escholarship.org/uc/item/5383w1mx
Breast Cancer Research : BCR
Breast Cancer Research : BCR
Introduction Various multigene predictors of breast cancer clinical outcome have been commercialized, but proved to be prognostic only for hormone receptor (HR) subsets overexpressing estrogen or progesterone receptors. Hormone receptor negative (HRn
Autor:
Douglas F. Lake, I. Tolgay Ocal, Heather E. Cunliffe, Benjamin A. Katchman, Yu Hui H. Chang, Janine LoBello, Galen Hostetter, Aprill Watanabe
Publikováno v:
Breast Cancer Research : BCR
Introduction Quiescin sulfhydryl oxidase 1 (QSOX1) oxidizes sulfhydryl groups to form disulfide bonds in proteins. Tumor specific expression of QSOX1 has been reported for numerous tumor types. In this study, we investigate QSOX1 as a marker of breas
Autor:
Annette M. Molinaro, Maria T Baquero, Karen Lostritto, David L. Rimm, Lyndsay Harris, Mark Gustavson, Franck Appia, Kimberly A Bassi, Robert L. Camp
Publikováno v:
Breast Cancer Research : BCR
Introduction Microtubule associated proteins (MAPs) endogenously regulate microtubule stabilization and have been reported as prognostic and predictive markers for taxane response. The microtubule stabilizer, MAP-tau, has shown conflicting results. W
Publikováno v:
Breast Cancer Research : BCR
Introduction Breast cancer comprises clinically distinct subtypes, but most risk statistics consider breast cancer only as a single entity. To estimate subtype-specific lifetime breast cancer risks, we took advantage of population-based data for whic